Logo image
Sign in
Back
LBO01 - Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
Journal article   Open access  Peer reviewed

LBO01 - Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

Stephen A. Harrison, Guy Neff, Cynthia Guy, Mustafa Bashir, Angelo Paredes, Juan Frias, Ziad H. Younes, James F. Trotter, Nadege T. Gunn, Sam Moussa, …
Journal of hepatology, Vol.73, pp.S114-S115
08/2020
DOI: https://doi.org/10.1016/S0168-8278(20)30750-9
url
https://doi.org/10.1016/S0168-8278(20)30750-9View
Published (Version of record) Open

Metrics

6 Record Views

Details